Related references
Note: Only part of the references are listed.The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
Cindy Neunert et al.
BLOOD (2011)
Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura
Michael R. Clausen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia
Zhenyu Li et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate
Roberto Stasi et al.
ANNALS OF HEMATOLOGY (2010)
International consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan et al.
BLOOD (2010)
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
Francesco Zaja et al.
BLOOD (2010)
Long-term follow-up of autoimmune thrombocytopenic purpura (ATP) patients submitted to splenectomy
Maria Gabriella Mazzucconi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Immune thrombocytopenia: A retrospective study of 40 patients
S. Audia et al.
REVUE DE MEDECINE INTERNE (2010)
Repeated courses of Rituximab in chronic ITP: Three different regimens
Aisha Hasan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP)
Kholood Alasfoor et al.
ANNALS OF HEMATOLOGY (2009)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero et al.
BLOOD (2009)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Kenneth R. Carson et al.
BLOOD (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating
Kenneth R. Carson et al.
LEUKEMIA & LYMPHOMA (2009)
Monoclonal antibodies and progressive multifocal leukoencephalopathy
Joseph R. Berger et al.
MABS (2009)
Splenectomy for immune thrombocytopenic purpura: Surgery for the 21st century
James P. Dolan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
Roberto Stasi et al.
BLOOD (2008)
Rituximab efficacy and. safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:: results of a prospective multicenter phase 2 study
Bertrand Godeau et al.
BLOOD (2008)
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results
Marta Medeot et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Rituximab off label use for difficult-to-treat auto-immune diseases: Reappraisal of benefits and risks
Laurent Sailler
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2008)
Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis
Jaime Garcia-Chavez et al.
ANNALS OF HEMATOLOGY (2007)
Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults
Drew Provan et al.
HAEMATOLOGICA (2007)
Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
Nichola Cooper et al.
CURRENT OPINION IN HEMATOLOGY (2007)
Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab
Christof Schweizer et al.
ANNALS OF HEMATOLOGY (2007)
Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
Donald M. Arnold et al.
ANNALS OF INTERNAL MEDICINE (2007)
Rituximab in the management of chronic immune thrombocytopenic purpura:: an effective and safe therapeutic alternative in refractory patients (vol 85, pg 558, 2006)
F. J. Penalver et al.
ANNALS OF HEMATOLOGY (2006)
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
N Cooper et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Monoclonal antibodies in the treatment of autoimmune cytopenias
T Robak
EUROPEAN JOURNAL OF HAEMATOLOGY (2004)
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
K Kojouri et al.
BLOOD (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP)
J Schwartz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
To the editor: Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura
R Stasi et al.
BLOOD (2002)
Medical progress: Immune thrombocytopenic purpura.
DB Cines et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
R Stasi et al.
BLOOD (2001)
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis
S Duval et al.
BIOMETRICS (2000)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
